Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EBP | Q15125 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893057 | 0.89 | HSD11B1 (0.41) | GBA1HSD11B1CNR1CNR2KDM4E | |
| SCHEMBL27126557 | 0.87 | GBA1 (0.40) | GBA1HSD11B1CNR1CNR2KDM4E | |
| SCHEMBL25681716 | 0.82 | GBA1 (0.30) | GBA1 | |
| SCHEMBL9893161 | 0.79 | HSD11B1 (0.34) | GBA1HSD11B1CNR1CNR2KCNH2 | |
| SCHEMBL8513384 | 0.76 | PDK1 (0.36) | GBA1 | |
| SCHEMBL9893048 | 0.74 | GBA1 (0.41) | GBA1HSD11B1CNR2 | |
| SCHEMBL9892987 | 0.74 | GBA1 (0.41) | GBA1HSD11B1CNR2 | |
| SCHEMBL12717512 | 0.74 | MAPK1 (0.36) | CNR1CNR2KDM4E | |
| SCHEMBL16480436 | 0.74 | MAPK1 (0.36) | CNR1CNR2KDM4E | |
| SCHEMBL9891495 | 0.72 | GBA1 (0.45) | GBA1HSD11B1CNR1CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | GBA1 1744/4885HSD11B1 3407/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.